Italia markets closed
FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
63.672,60 +1.424,36 (+2,29%)
Idorsia Ltd (0RQE.L)
LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
Alla chiusura: 08:20AM BST
| Chiusura precedente | 12,25 |
| Aperto | 11,76 |
| Denaro | 0,00 x 0 |
| Domanda | 0,00 x 0 |
| Min-Max giorno | 11,40 - 11,76 |
| Intervallo di 52 settimane | 2,87 - 17,80 |
| Volume | |
| Media Volume | 102.892 |
| Capitalizzazione | 1,498B |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,26 |
| Prossima data utili | 25 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireIdorsia reacquires the world-wide rights to aprocitentan
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia’s oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resistant hypertension.Idorsia will pay Janssen a conditional consideration up to a total cap of CHF 306 millionIdorsia is initiating activities to determine the best approach to maximize the value of aprocitentan. Allschwil, Switzerland – September 6, 2023Idorsia Ltd (SIX: IDIA) today announced that it h
© 2024 Yahoo. Tutti i diritti riservati.